Abstract 26P
Background
10% of colorectal cancers (CRC) have a BRAF mutation (BM). This is a poor prognostic group with distinct clinical characteristics. Robust preclinical models that reflect this CRC subtype are currently lacking. We have developed a novel, aggressive, immune competent, genetically engineered mouse model (GEMM) that aligns well with human BM CRC.
Methods
4 genes were targeted with the villinCreER: activating Braf V600E/+ (B), deletion of Trp53 fl/fl (P), deletion of ALK5fl/fl and NOTCH1 intracellular domain expression Rosa26 N1icd/+ (N). This generated BPNA mice. Mice were induced and aged until clinical endpoint. Clinically relevant treatments were benchmarked, including BRAFi (Dabrafenib) combined with EGFRi (Erlotinib). Mouse tumour organoids were derived and high throughput drug screening was performed.
Results
BPNA mice developed endpoint tumours in the proximal colon in a short time period (37 DPI). Mice had high rates of T4 disease (57%) and, despite short latency, developed peritoneal metastasis in 5/27 mice (19%). Primary tumours had proficient mismatch repair (pMMR). Tumours classified as CMS4, aligned with the BM1 transcriptional subtype and displayed regenerative cancer stem cell markers. Therapeutic interventions based on the BEACON CRC (BRAFi+EGFRi) combinations were tested. Both BRAFi and EGFRi as monotherapies had no significant survival advantage (OS) in vivo. However in combination, mice lived twice as long with median OS of the combination group 66 DPI vs 32 DPI in the vehicle control (log-rank p<0.001). DUSP6 was only significantly suppressed in the BRAF/EGFRi arm suggesting effective MAPK targeting requires combination therapy. Through organoid drug screening, 28/166 compounds were identified as hits of which 3/5 top hits were proteasome inhibitors.
Conclusions
The BPNA GEMM aligns with human disease in terms of primary tumour characteristics and metastatic pattern. Mice also respond to standard of care therapeutics similarly to humans creating a good benchmark for further investigation. Organoid drug screens have highlighted a potentially novel drug class for BM CRC treatment. Future work will utilize these mice to test therapeutics enabling robust pre-clinical evidence to de-risk future novel early phase trials for BM CRC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Cancer Research UK.
Disclosure
O.J. Sansom: Financial Interests, Institutional, Funding: Novartis, Cancer Research Technology, Redx. All other authors have declared no conflicts of interest.
Resources from the same session
68P - Dendritic polylysine with paclitaxel and triptolide codelivery for enhanced NSCLC ferroptosis through the accumulation of ROS
Presenter: Huae Xu
Session: Poster session 09
69P - Novel monoclonal antibodies can distinguish Cripto-1 from Cripto-3 proteins: Clinical implications and potential new biomarkers
Presenter: Josune Garcia-Sanmartin
Session: Poster session 09
70P - The human intratumor mycobiome is significantly influenced by an individual's race
Presenter: Dan Coster
Session: Poster session 09
71P - Preclinical characterization of ARX305: A next-generation anti-CD70 antibody drug conjugate for the treatment of CD70-expressing cancers
Presenter: Lillian Skidmore
Session: Poster session 09
72P - Impact of extended panel of genes for germline cancer testing
Presenter: Shaheenah Dawood
Session: Poster session 09
73P - Preclinical and clinical presentation of the nerve-driven tumor spread
Presenter: Dawid Sigorski
Session: Poster session 09
74P - Characterization of ERBB2 variation and their association with immune response in solid tumours
Presenter: Dong Wang
Session: Poster session 09
75P - Double-stranded RNA transfection induced anti-tumour effect mediated by dual RIG-I and TLR-3 immune pathways
Presenter: Jiayu Tai
Session: Poster session 09
76P - Improvement of whole-cell cancer vaccine anti-tumor effect by different injection methods
Presenter: Chin yang Chang
Session: Poster session 09
77P - Normative data on the sexual health questionnaires - QLQ-SHQ22, and the sexual domains of the QLQ-BR23/BR45 - for Norwegian general population with and without cancer
Presenter: Ragnhild Åsberg
Session: Poster session 09